Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Pharmaco-genomics Pharmaco-metabolomics Pharmaco-transcriptomics Pharmaco-proteomics Search

Displaying entries 44326 - 44350 of 102031 in total

Drug	Drug Groups	Gene	Gene ID	Change	Interaction	Chromosome	References
							Clear
Fulvestrant	Approved Investigational	ATP5B	506	upregulated	fulvestrant results in increased expression of ATP5B mRNA	12q13.3	A21141
Fulvestrant	Approved Investigational	AURKA	6790	downregulated	fulvestrant results in decreased expression of AURKA mRNA	20q13.2	A20479
Fulvestrant	Approved Investigational	AURKB	9212	downregulated	fulvestrant results in decreased expression of AURKB mRNA	17p13.1	A22729
Fulvestrant	Approved Investigational	BIRC5	332	downregulated	fulvestrant results in decreased expression of BIRC5 mRNA	17q25.3	A22729
Fulvestrant	Approved Investigational	BRCA1	672	downregulated	fulvestrant results in decreased expression of BRCA1 mRNA	17q21.31	A21158
Fulvestrant	Approved Investigational	BUB1	699	downregulated	fulvestrant results in decreased expression of BUB1 mRNA	2q13	A22729
Fulvestrant	Approved Investigational	BUB1B	701	downregulated	fulvestrant results in decreased expression of BUB1B mRNA	15q15.1	A22729
Fulvestrant	Approved Investigational	CA12	771	downregulated	fulvestrant results in decreased expression of CA12 mRNA	15q22.2	A21106
Fulvestrant	Approved Investigational	CASP4	837	upregulated	fulvestrant results in increased expression of CASP4 mRNA	11q22.3	A20482
Fulvestrant	Approved Investigational	CBX1	10951	downregulated	fulvestrant results in decreased expression of CBX1 mRNA	17q21.32	A20479
Fulvestrant	Approved Investigational	CCL20	6364	upregulated	fulvestrant results in increased expression of CCL20 mRNA	2q36.3	A21168
Fulvestrant	Approved Investigational	CCL5	6352	upregulated	fulvestrant results in increased expression of CCL5 mRNA	17q12	A20482
Fulvestrant	Approved Investigational	CCNA2	890	downregulated	fulvestrant results in decreased expression of CCNA2 mRNA	4q27	A21102 A22729
Fulvestrant	Approved Investigational	CCNB1	891	upregulated	fulvestrant results in increased expression of CCNB1 mRNA	5q13.2	A20482
Fulvestrant	Approved Investigational	CCNB2	9133	downregulated	fulvestrant results in decreased expression of CCNB2 mRNA	15q22.2	A22729
Fulvestrant	Approved Investigational	CCND1	595	downregulated	fulvestrant results in decreased expression of CCND1 mRNA	11q13.3	A21158 A22730 A22731 A22732 A21106 A21186
Fulvestrant	Approved Investigational	CCNE1	898	downregulated	fulvestrant results in decreased expression of CCNE1 mRNA	19q12	A22730
Fulvestrant	Approved Investigational	CCNE2	9134	downregulated	fulvestrant results in decreased expression of CCNE2 mRNA	8q22.1	A22729
Fulvestrant	Approved Investigational	CCNG2	901	upregulated	fulvestrant results in increased expression of CCNG2 mRNA	4q21.1	A21106
Fulvestrant	Approved Investigational	CD24	100133941	upregulated	fulvestrant results in increased expression of CD24 mRNA	6q21	A20479
Fulvestrant	Approved Investigational	CD44	960	downregulated	fulvestrant results in decreased expression of CD44 mRNA	11p13	A21106
Fulvestrant	Approved Investigational	CDC20	991	downregulated	fulvestrant results in decreased expression of CDC20 mRNA	1p34.2	A22729
Fulvestrant	Approved Investigational	CDK1	983	downregulated	fulvestrant results in decreased expression of CDK1 mRNA	10q21.2	A22729
Fulvestrant	Approved Investigational	CDK2	1017	upregulated	fulvestrant results in increased expression of CDK2 mRNA	12q13.2	A22730
Fulvestrant	Approved Investigational	CDKN1A	1026	upregulated	fulvestrant results in increased expression of CDKN1A mRNA	6p21.2	A20482 A21195

Displaying entries 44326 - 44350 of 102031 in total

Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Advanced Filter

Filter by Group

Filter by Market Availability